Inactive Instrument

Gujarat Themis Biosyn Ltd Share Price Bombay S.E.

Equities

GTHM

INE942C01029

Pharmaceuticals

End-of-day quote Bombay S.E.
- - Intraday chart for Gujarat Themis Biosyn Ltd

Financials

Sales 2022 1.15B 13.74M 0 1.08B Sales 2023 1.49B 17.82M 0 1.41B Capitalization 9.97B 119M 0 9.41B
Net income 2022 436M 5.22M - 411M Net income 2023 580M 6.94M - 547M EV / Sales 2022 4.97 x
Net cash position 2022 209M 2.5M 0 197M Net cash position 2023 84.84M 1.02M 0 80.06M EV / Sales 2023 6.64 x
P/E ratio 2022
13.6 x
P/E ratio 2023
17.2 x
Employees -
Yield 2022
1.47%
Yield 2023
0.79%
Free-Float 27.98%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer - 06/08/14
Director of Finance/CFO - -
Compliance Officer - 11/05/21
Members of the board TitleAgeSince
Director/Board Member 67 30/03/06
Director/Board Member 49 24/10/08
Chairman 75 24/05/92
More insiders
Gujarat Themis Biosyn Limited is an India-based company, which is principally engaged in the manufacturing of pharmaceuticals and medicinal chemical products. The Company is focused on the business of manufacturing and sale of finished active pharmaceutical ingredients (API) products by fermentation process. The Company operates through manufacturing of the bulk drugs segment. Its product portfolio comprises Rifamycin-O and Rifamycin-S. The Company is manufacturing Rifamycin S, which is an intermediate for manufacturing the drug Rifampicin (an Antibiotic used for the treatment of several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease.) and Rifamycin O, which is an intermediate for manufacturing the drug Rifaximin (this is an Antibiotic used for treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy). Its research and development division focuses on developing fermentation cultures.
Calendar
More about the company